Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Osterweis Fund (OSTFX)

Net Asset Value
1 Day
Overall Morningstar Rating
Mid-cap blend
Style or Category
No Load
Sales Expenses
Expense Ratio
Morningstar Risk Rating™
Investment Objective The investment seeks long-term total return. The fund invests primarily in common stocks of companies that Osterweis Capital Management, Inc. believes offer superior investment value and opportunity for growth. It may invest in companies of any size - large, medium and small. The Adviser focuses on companies that the adviser believes to be undervalued or otherwise out-of-favor in the market, but that have attractive growth prospects. It may invest up to 30% of its assets in equity securities of foreign issuers and/or depositary receipts that are traded on domestic or foreign exchanges, including emerging markets.


1 month+1.97% 3 years+1.97%
3 months+4.27% 5 years+9.45%
1 year+15.90% Since inception+10.12%
Data through --

Peer Comparisonvs. Mid-cap blend

Performance 5-yr return+9.45%+13.32%
Expense ratio1.03%1.13%
Risk 5 year sharpe ratio0.911.10
Net assets$420.3M$1.9B
Average market cap$32.6B$6.9B
Average P/E20.120.5
Portfolio turnover20%20%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyOsterweis
Fund manager & tenureJohn Osterweis / 23 Years
Minimal initial investment$5,000.00
Minimum IRA investment$1,500.00


U.S. stock77.53%
International stock13.61%
Fixed income0.00%
Top 5 Sectors
Portfolio weighting
Healthcare 20.69%
Energy 19.88%
Industrial materials 10.60%
Consumer goods 10.57%
Financial service 9.14%
Top 10 Holdings
Portfolio weighting
CHTR Charter Communications Inc5.63%
GOOG Google4.87%
CNK Cinemark Holdings Inc4.01%
EPR EPR Properties3.82%
CCK Crown Holdings Inc3.78%
AGN Allergan3.68%
MMP Magellan Midstream Partners LP3.15%
LBTYK Liberty Global PLC3.09%
GSK GlaxoSmithKline3.03%
JNJ Johnson & Johnson3.01%